Are we still talking to our patients with schizophrenia?

American Journal of Psychiatry

Volumn 163, Issue 3, 2006, Pages 362-364

  Keith, Samuel J ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; COGNITIVE THERAPY; DRUG FORMULATION; EDITORIAL; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; PSYCHOANALYSIS; SCHIZOPHRENIA; UNITED STATES; DOCTOR PATIENT RELATION; EDUCATION; HEALTH PERSONNEL ATTITUDE; METHODOLOGY; PSYCHIATRY; PSYCHOLOGY; STANDARD; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; COGNITIVE THERAPY; HUMANS; PHYSICIAN-PATIENT RELATIONS; PSYCHIATRY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES;

EID: 33645953639     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.163.3.362     Document Type: Editorial

References (13)

1. Laing RD: The Politics of Experience. New York, Ballantine, 1967
2. Mosher LR, Menn AZ: Community residential treatment for schizophrenia: a two-year follow-up. Hosp Community Psychiatry 1978; 29:715-723
3. Lieberman J, Stroup S, McEvoy J, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B, Severe J, Hsiao J: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 363:1209-1221
4. Tarrier N, Yusupoff L, Kinney C, McCarthy C, Gledhill A, Haddock G, Morris J: Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. BMJ 1998; 317:303-307
5. Tarrier N, Wittkowski A, Kinney C, McCarthy C, Morris J, Humphreys L: Durability of the effects of cognitive-behavioural therapy in the treatment of schizophrenia: 12-month follow-up. Br J Psychiatry 1999; 174:500-504
6. Tarrier N, Kinney C, McCarthy E, Humphreys L, Wittkowski A, Morris J: Two-year follow-up of cognitive-behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia. J Consult Clin Psychol 2000; 68:917-922
7. Sensky T, Turkington D, Kingdon D, Scott JL, Scot J, Siddle R, O'Carroll M, Barnes TRE: A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms of schizophrenia resistant to medication. Arch Gen Psychiatry 2000; 57:165-172
8. Kemp R, Hayward P, Applewhaite G, Everitt B, David A: Compliance therapy in psychotic patients: a randomized controlled trial. BMJ 1996; 312:345-349
9. Kemp R, Kirov G, Everitt B, Hayward P, David A: Randomized controlled trial of compliance therapy: 18 month follow-up. Br J Psychiatry 1998; 172:413-419
10. O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, Kinsella A, Larkin C, O'Callaghan E: Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003; 327:834
11. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928
12. Wagemaker H Jr, Cade R: The use of hemodialysis in chronic schizophrenia. Am J Psychiatry 1977; 134:684-685
13. Kline N, Li C, Lehmann H, Lajtha A, Laski E, Cooper T: Beta-endorphin-induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 1977; 34:1111-1113